NSABP B-47: A phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of docetaxel plus cyclophosphamide or four cycles of doxorubicin plus cyclophosphamide followed by weekly paclitaxel) to chemotherapy plus trastuzumab in women with node-positive or high-risk, node-negative, HER2-low invasive breast cancer.

Authors

Louis Fehrenbacher

National Surgical Adjuvant Breast and Bowel Project and Kaiser Permanente Northern California, Vallejo, CA

Louis Fehrenbacher , Jong-Hyeon Jeong , Priya Rastogi , Charles E. Geyer Jr., Soonmyung Paik , Patricia A. Ganz , Stephanie R. Land , Joseph P. Costantino , Sandra M. Swain , Eleftherios P Mamounas , Norman Wolmark

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer.

First Author: Louis Fehrenbacher

insert_chart_outlined

Poster

2015 Breast Cancer Symposium

bookmark_border

Review of trends in adjuvant chemotherapy regimens in breast cancer over 10 year period at Yale New Haven Hospital (YNHH).

First Author: Rosana Gnanajothy

insert_chart_outlined

Poster

2012 Breast Cancer Symposium

bookmark_border

Adjuvant chemotherapy for early-stage breast cancer: Choice of regimen and associated hematologic toxicities in a metropolitan Australian hospital.

First Author: Katherine Lovat

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

Phase I/II trial of partial breast irradiation (PBI) with various concurrent chemotherapy regimens.

First Author: Lana Maria De Souza Lawrence